Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior...

MLA

Curigliano, Giuseppe, et al. “Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (Pts) with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (MBC) with Prior..” Journal of Clinical Oncology, vol. 42, June 2024, p. LBA1000. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA1000.

APA

Curigliano, G., Hu, X., Dent, R. A., Yonemori, K., Barrios Sr., C. H., O’Shaughnessy, J., Wildiers, H., Zhang, Q., Im, S.-A., Saura, C., Biganzoli, L., Sohn, J., Levy, C., Jacot, W., Begbie, N., Ke, J., Patel, G. S., & Bardia, A. (2024). Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior.. Journal of Clinical Oncology, 42, LBA1000. https://doi.org/10.1200/JCO.2024.42.17_suppl.LBA1000

Chicago

Curigliano, Giuseppe, Xichun Hu, Rebecca Alexandra Dent, Kan Yonemori, Carlos H. Barrios Sr., Joyce O’Shaughnessy, Hans Wildiers, et al. 2024. “Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (Pts) with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (MBC) with Prior..” Journal of Clinical Oncology 42 (June): LBA1000. doi:10.1200/JCO.2024.42.17_suppl.LBA1000.